A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients

Leukemia

Volumn 18, Issue 9, 2004, Pages 1518-1521

  Rousselot, P ^a   Larghero, J ^a   Arnulf, B ^a   Poupon, J ^b   Royer, B ^a   Tibi, A ^c   Madelaine Chambrin, I ^a   Cimerman, P ^d   Chevret, S ^a   Hermine, O ^e   Dombret, H ^a   Brouet, J Claude ^a   Fermand, J Paul ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL FERNAND WIDAL   (France)

^c Hopitaux de Paris   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Arsenic trioxide; Clinical trial; Myeloma; Pharmacokinetic

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; CLOBAZAM; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; M PROTEIN; MELARSOPROL; PARAPROTEIN; THIAMINE; VINCRISTINE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL STUDY; CONFUSION; CONTROLLED STUDY; CYTOLYSIS; CYTOPENIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; ENCEPHALITIS; FEMALE; HEPATITIS; HERPES ZOSTER; HUMAN; LIVER TOXICITY; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SOMNOLENCE; THROMBOCYTOPENIA; WHOLE BODY RADIATION; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SALVAGE THERAPY; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OXIDES; SALVAGE THERAPY;

EID: 4444275232     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403424     Document Type: Article

References (19)

1. Sun HD, Ma L, Hu XC. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992; 1: 170-171.
2. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
3. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
4. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R et al. Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334.
5. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126: 441-447.
6. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and plasma cells from myeloma patients. Cancer Res 1999; 59: 1041-1048.
7. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependant kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
8. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
9. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependant G1 G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078-4087.
10. Rousselot P, Larghero J, Labaume S, Chopin M, Dosquet C, Marolleau JP et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72: 166-171.
11. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355: 1419-1425.
12. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16: 1835-1837.
13. Hussein MA, Mason J, Saleh NM, Rifkin RM, Ravandi F. Arsenic trioxide (Trisenox) in patients with relapsed or refractory multiple myeloma (MM): final report of a phase II clinical study. Blood 2002; 100: 5138a.
14. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
15. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
16. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805-813.
17. Borad M, Swift RA, Sadler K, Yang H, Berenson JR. Melphalan, arsenic trioxide and ascorbic acid (MAC) is effective in the treatment of refractory and relapsed multiple myeloma (MM). Blood 2003; 102: 827a.
18. Birch R, Schwartzberg LS, Lawrence V, Schnell FM, Tongol JM, Prill SJ et al. A phase II study of arsenic trioxide (ATO) in combination with dexamethasone (Dex) and ascorbic acid (VITC) in patients with relapsed/refractory multiple myeloma. Blood 2003; 102: 5271a.
19. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.